title: [Modern methods of energy homeostasis correction in elderly patients].
abstract: In the multicenter randomized clinical-instrumental prospective study 185 patients aged 55-75 years (mean age 68 years) with 94 men and 91 women with cerebral infarction were included. All the patients were hospitalized in the period from 6 to 24 hours from the time of the debut of clinical symptoms, 42,2% of patients scored 14 and above on NIH scale on admission. Patients were randomized into 3 groups: 1st group consisted of 64 patients treated as an antioxidant by 5% solution of ascorbic acid 2 times a day the recommended dose (20 ml/day) for 20 days; 2nd group consisted of 72 patients who received energy monitor Cytoflavin in a daily dose of 20 ml (10.0 ml/drip 2 times a day for 10 days); 3rd group consisted of 49 patients with Cytoflavin therapy extended to 20 days, moreover from 11th to 20th day the dose was 10 ml/day. Cytoflavin treatment was more efficient than ascorbic acid, which can be explained by different pharmacologic mechanisms. Treatment with Cytoflavin for 10 days resulted in a significant decrease of ischemia zone volume by 25% in average, treatment with Cytoflavin for 20 days--by 29%, which manifested in better outcomes in neurologic and functional status. Ascorbic acid demonstrated no effect on morphologic parameters. Patients having at the time of admission 18-20 points according to the NIH and treated with Cytoflavin for 20 days demonstrated significant trend towards improvement of the parameters of the neurological status.
authors.forename: S A
authors.initials: SA
authors.lastname: Rumiantseva
authors.forename: E V
authors.initials: EV
authors.lastname: Silina
authors.forename: L A
authors.initials: LA
authors.lastname: Tsukurova
authors.forename: V A
authors.initials: VA
authors.lastname: Stupin
authors.forename: L V
authors.initials: LV
authors.lastname: Chichanovskaia
authors.forename: M V
authors.initials: MV
authors.lastname: Nazarov
authors.forename: A L
authors.initials: AL
authors.lastname: Kovalenko
authors.forename: E N
authors.initials: EN
authors.lastname: Kabaeva
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000975:Antioxidants / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004734:Energy Metabolism / Q000187:drug effects*; D005260:Female; D005486:Flavin Mononucleotide / Q000008:administration & dosage / Q000627:therapeutic use*; D006706:Homeostasis / Q000187:drug effects*; D006801:Humans; D007290:Inosine Diphosphate / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D012720:Severity of Illness Index; D020521:Stroke / Q000188:drug therapy* / Q000378:metabolism; D013386:Succinates / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D004338:Drug Combinations; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate; D001205:Ascorbic Acid